|Publication number||US6060080 A|
|Application number||US 08/409,924|
|Publication date||May 9, 2000|
|Filing date||Mar 23, 1995|
|Priority date||Jul 16, 1990|
|Publication number||08409924, 409924, US 6060080 A, US 6060080A, US-A-6060080, US6060080 A, US6060080A|
|Inventors||Hiroshi Kikuchi, Kiyoto Yachi, Sadao Hirota|
|Original Assignee||Daiichi Pharmaceutical Co., Ltd.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (12), Non-Patent Citations (4), Referenced by (61), Classifications (5), Legal Events (5)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This is a Continuation of application Ser. No. 08/007,050 filed Jan. 21, 1995, now abandoned, which is a Continuation-in-Part of application Ser. No. 07/729,266 filed Jul. 12, 1991 (abandoned).
This invention relates to liposomal products comprising a cation moiety-containing water-soluble drug and, as membrane components, an anionic phospholipid and cholesterol. The liposomal products according to the invention is superior in drug encapsulation efficiency, in stability in blood and, furthermore, in storage stability.
Liposomes are widely used as models of biomembranes. Furthermore, they have recently been energetically investigated as a typical example of the drug delivery system (DDS).
However, when a water-soluble drug is encapsulated in liposomes by the conventional method, the encapsulation efficiency of drugs is generally low (in most cases 0.1 to 20%). There are two reasons: i) the mode of encapsulation of a low molecular weight water-soluble drug in liposomes basically consists distribution of the drug in the same concentration between the inner aqueous phase and outer aqueous phase of the liposomes and ii) for making liposomes stable as separate particles in an aqueous medium, it is necessarily required that the aqueous medium be present externally to liposomes as a dispersion medium therefor.
In view of the above, it has been considered very difficult to raise the drug encapsulation efficiency, in particular to a level close to 100%, when a water-soluble drug is caused to be encapsulated in liposomes.
Known methods for increasing the encapsulation efficiency of such a water-soluble drug or a drug having a small affinity for membranes include, among others, a) a reversed phase evaporation method (Proceedings of National Academy Sciences of U.S.A., 75, 4194, 1978), b) a chemical modification of drugs themselves (International Journal of Pharmaceutics, 14, 191, 1983; Journal of Pharmacobiodynamics, 7, 120, 1984; Chemical and Pharmaceutical Bulletin, 36, 3574, 1988), c) a use of other auxiliaries or the like (Journal of Pharmaceutical Sciences, 71, 958, 1982; Drug Development and Industrial Pharmacy, 10, 613, 1984), d) a modification of the properties of liposomal membranes themselves (Biochimica et Biophysica Acta, 812, 66, 1985; Biochimica et Biophysica Acta, 857, 123, 1986), and e) a use of a phospholipid having a charge opposite to the charge of the drug (Biochemical and Biophysical Research Communications, 107, 136, 1982; International Journal of Pharmaceutics, 17, 135, 1983; U.S. Pat. No. 4,769,250.
The prior art methods such as mentioned above are not satisfactory when a cation moiety-containing water-soluble drug is to be efficiently encapsulated in liposomes. In addition, when viewed as products for medical use, the liposomal products given by the prior art methods are quite unsatisfactory from the viewpoint of stability in blood.
As a result of extensive investigation to improve the above problems, it has been found that liposomal products comprising a cation moiety-containing water-soluble drug and, as membrane components, an anionic phospholipid and cholesterol is superior in drug encapsulation efficiency and also is very stable in blood or during storage. Based on the findings, the present invention has been completed.
Object of this invention is to provide liposomal products having a very high drug encapsulation efficiency and a very high stability in blood or during storage which can be produced with good reproducibility.
The above object of this invention can be accomplished by a liposomal products which comprises: a liposomal membrane comprising an anionic phospholipid and cholesterol as essential components; and a cation moiety-containing water-soluble drug whose encapsulation efficiency is very high.
The anionic phospholipid to be used in the invention includes, among others, anionic phospholipids having saturated or unsaturated, straight or branched fatty acid residues containing about 10 to 30 carbon atoms, preferably saturated, straight or branched fatty acid residues containing about 14 to 16 carbon atoms and/or unsaturated, straight or branched fatty acid residues containing about 14 to 20 carbon atoms, such as phosphatidic acids and phsophatidylglycerols, more particularly dimyristoylphosphatidylglycerol, dipalmitoylphosphatidyl-glycerol, phosphatidylglycerols derived from naturally occurring substances such as egg yolk and soybean, completely hydrogenated phosphatidylglycerols, distearoylphosphatidyl-glycerol and the like. Preferred examples are dimyristoyl-phosphatidylglycerol, dipalmitoylphosphatidylglycerol, egg yolk-derived phosphatidylglycerol and the like. Dimyristoylphosphatidylglycerol is the most preferred. The anionic phospholipid is used generally in an amount of not less than 2, preferably 3 to 20 on the ionic equivalent basis relative to the used drug. Simply, the anionic phospholipid can be used in an amount of not less than 2 moles, preferably 3 to 20 moles per mole of the used drug.
Cholesterol, which is one of the liposomal membrane components to be used in accordance with the invention, is used generally in a mole percent of about 30 to 60%, preferably 40 to 55%, to the total amount of the membrane components used.
The liposomal membrane used in the invention may contain, in addition to the above-mentioned two components, a neutral phospholipid such as a phosphatidylcholine or sphingomyelin, and an antioxidant such as α-tocopherol. The neutral phospholipid mentioned above is generally used in a mole fraction of 0 to 40% preferably 0 to 35% and 0 to 30% and most preferably 0 to 20% based on the total amount of the membrane components used while the above-mentioned antioxidant is generally used in a mole percent of not more than about 5% on the same basis.
The aqueous medium in the liposomal products which is present inner and outer of the liposomes according to the invention is described below.
For assuring the stability of liposomes and drugs, the aqueous medium should generally have a pH of about 3 to 8. For the stability of liposomes, the pH should preferably be 6 to 8. Since the pH at which the drug is stable may differ drug by drug, the pH of the aqueous medium of the liposomal product according to the invention should suitably be determined within the pH range in which liposomes themselves are stable and in which the drug is stable. Thus, for instance, when such a drug as doxorubicin hydrochloride is used, the aqueous medium in the resulting liposomal product may have a pH of about 4.
Typical examples of the acid used for this pH adjustment include a monovalent inorganic acid such as hydrochloric acid, nitric acid or hydrobromic acid, or a monovalent organic acid such as lactic acid, glyceric acid or acetic acid. Hydrochloric acid and lactic acid are preferred, however. The base for such pH adjustment includes monovalent hydroxides such as potassium hydroxide, sodium hydroxide and lithium hydroxide, and monovalent amines such as triethylamine, trimethylamine, diisopropanolamine, diethanolamine, triethanolmaine, tetramethylamine and tris(hydroxymethyl)aminomethane. Among these, potassium hydroxide and sodium hydroxide are preferred. Furthermore, acids containing a divalent or trivalent ion, such as potassium primary phosphate, sodium secondary phosphate and sodium carbonate, may also be used.
The electrolyte ion concentration in the aqueous medium should desirably be as low as possible and, generally, the total concentration of ions except the drug should suitably be not more than about 40 mM. An anionic phospholipid usually can be obtained in the form of sodium or calcium salt. Therefore, the amount of the electrolyte derived therefrom must be taken into account.
The osmotic pressure of the aqueous medium preferably be equal or close to that of body fluids. Preferred isotonizing agents to be used therefor include polyhydric alcohols such as glycerol and propylene glycol, and saccharides such as mannitol, sucrose, glucose and lactose.
The liposomes suited for use in this invention are now described below in detail.
From the viewpoint of stability in blood, the liposomes should generally have a particle size of about 50 to 1,000 nm, preferably 60 to 300 nm, more preferably 70 to 200 nm. For sizing of liposomes to attain such a particle size, techniques in general use may be employed, for example emulsification treatment using an ultrasonicator, or extrusion treatment through a polycarbonate membrane filter under high pressure. From the stability-in-blood viewpoint, it is desirable that the liposomes according to the invention have a plurality of membranes. The number of membranes is not limited to any particular value or range. Such liposomes can be produced by suitably using such a conventional sizing technique as mentioned above, in particular the extrusion technique.
The term "cation moiety-containing water-soluble drug" as used herein means a water-soluble drug forming a cation in aqueous solution (neutral pH region) and includes, as typical examples thereof, anthracycline antitumor agents such as doxorubicin hydrochloride, daunorubicin hydrochloride, epirubicin and pirarubicin, and antimicrobial agents such as gentamicin and nystatin, among others.
The process for preparing of the liposomal products according to this invention is described below.
According to the various known methods, for example the method disclosed in Journal of Molecular Biology, 13, 238 (1965), the liposomal membrane components mentioned above are first dissolved in an appropriate organic solvent, such as chloroform or methanol, and then the solvent is distilled off to cause formation of a lipid film. From the efficiency viewpoint, it is advantageous that the drug such as mentioned above be admixed in advance with the membrane components, although the drug may also be dissolved in advance in the aqueous medium to be added later. To the lipid film aqueous medium is added in a low electrolyte concentration such that the total concentration of ion except the drug is not more than 40 mM, and preferably not more than 20 mM, to thereby cause hydration and swelling. Dispersion is further effected using a mixer such as a vortex mixer or an agitating/homogenizing mixer to give a crude liposomal dispersion. In this step, when the temperature of the aqueous medium is higher, a higher emulsification efficiency will be obtained. However, when the temperature is extremely high, the drug may be decomposed in certain instances. Caution is needed accordingly. Generally, a temperature within the range of 50° to 70° C. can preferably be used. The aqueous medium to be added in this step may contain a buffer, such as phosphoric acid or lactic acid. The electrolyte ion concentration in the medium should be not more than 40 mM in total except the drug, as mentioned above, and the pH should suitably be selected generally within the range of 3 to 8. When doxorubicin hydrochloride, for instance, is used as the drug, the pH should be adjusted to about 4 and a polyhydric alcohol or a saccharide may be added as an isotonizing agent, as mentioned above. In this step, such crude liposomal dispersion may be produced by any other known method for preparation of liposomes (e.g. Annual Review of Biophysics and Engineering, 9, 467, 1980; JP-A-60-7932, JP-A-60-7933, JP-A-60-7934, JP-A-60-12127 and JP-A-62-152531, "JP-A" as used herein means an "unexamined published Japanese patent application").
Since the thus-obtained crude dispersion generally has a liposome particle size of about 1 μm, the dispersion may, as desired, be converted to a homogenized liposomal dispersion with a smaller particle size in a step of sizing. The sizing may be effected, as mentioned above, by emulsifying treatment using an ultrasonicator, a Manton-Gaulin homogenizer, a microfluidizer or the like homogenizing mixer and/or extrusion treatment under high pressure through a polycarbonate membrane filter with a certain specified pore size.
With the liposomal membrane formulation in accordance with the invention, liposomes having a particle size of 50 to 200 nm can generally be obtained with a desired number of membranes by passing the crude liposomal dispersion once or twice through a polycarbonate membrane filter having a pore size of 0.2 μm under high pressure. In this step almost no residue remains on the filter. The fact that the liposomes obtained have a plurality of membranes can be confirmed by observation under an electron microscope and on the basis of an estimated value derived from the encapsulation volume, L (liters)/M (mole), as determined for a water-soluble model drug and the particle size. More preferably, the crude dispersion should be passed once through a filter with a large pore size (e.g. 0.6 μm) prior to the passage through a filter with a pore size of 0.2 μm so that larger-size particles can preliminarily be sized and foreign materials and insoluble materials can be removed in advance. In the above sizing step, a higher efficiency can generally be obtained when the temperature of the aqueous medium is higher. At an extremely high temperature, however, the drug may be decomposed chemically. A temperature between 50° and 70° C. is generally preferable and appropriate.
The thus-obtained liposomal dispersion is submitted to the final preparation step. The pH may be readjusted in advance to a desired level using a low concentration aqueous solution of sodium hydroxide or potassium hydroxide or the like such as mentioned above. It goes without saying that the total electrolyte ion concentration (except the drug) should desirably be 40 mM or below. The final step is generally started with bacterial filtration. More specifically, the aqueous dispersion of liposomes as obtained in the above manner is passed through a membrane filter with a pore size of 0.4 μm to 0.2 μm. Then, when the liposomal products according to the invention are in the form of an aqueous dispersion, the filtrate is distributed as such in portions as desired into ampules or other containers, which are then sealed. When a frozen preparation is desired, the contents in the sealed containers are frozen at -5° to -80° C., preferably -30° to -40° C. Furthermore, when a lyophilized preparation is desired, the filtrate is distributed into vials or other containers and then subjected to lyophilization in a conventional manner. Desirable lyophilization conditions are as follows: rapid freezing should be attained at a freezing temperature of -5° to -80° C., preferably -30° to -40° C. and water should be sublimed at a reduced pressure of 0.1 torr or below. Finally, when a spray-dried preparation is desired, the above-mentioned aqueous liposomal dispersion is spray-dried for solvent removal and the powder obtained is distributed under aseptic conditions into vials or other appropriate containers, which are then sealed. Spray-drying conditions which are desirable include an inlet temperature of 110° to 200° C., preferably 120° to 150° C.
The present invention makes it possible to produce liposomal products with a very high drug encapsulation efficiency and with good reproducibility. Furthermore, the liposomal products according to the invention are highly stable in the blood and, in addition, are excellent in liposome stability and drug encapsulation efficiency during storage irrespective of whether they are aqueous dispersion preparations or lyophilized preparations. Thus, the invention provides very excellent liposomal products.
The present invention is now illustrated in greater detail by way of the following examples, but it should be understood that the present invention is not deemed to be limited thereto. The preparative procedures, analytical methods and so forth which are identical throughout the examples are first described in the following. The charged lipids used in examples 1 to 20 were sodium salts. Those used in Examples 21 and 22 were in the free state.
1. Organic Solvent Method A:
The lipid membrane components and doxorubicin hydrochloride were placed in a glass container and once completely dissolved in a mixture of chloroform and methanol. The organic solvents were then distilled off under a nitrogen gas stream or under reduced pressure, followed by further drying in a desiccator (under reduced pressure). A lactate buffer (9 mM) isotonized substantially to the biological osmotic pressure was then added thereto, and the whole was agitated with a vortex mixer or agitating/homogenizing mixer with gentle warming to give a crude dispersion of liposomes.
2. Organic Solvent Method B:
The lipid membrane components were placed in a glass container and once completely dissolved in a mixture of chloroform and methanol. The organic solvents were then distilled off under a nitrogen gas stream or under reduced pressure, followed by further drying in a desiccator (under reduced pressure). Then, a solution of doxorubicin hydrochloride in the above-mentioned buffer substantially isotonic to the biological osmotic pressure or a buffer containing 10% sucrose was added thereto, and the whole was agitated with a vortex mixer or agitating/homogenizing mixer with gentle warming to give a crude dispersion of liposomes.
3. Polyhydric Alcohol Method:
A necessary amount of glycerol was placed in a glass container and heated. The lipid membrane components were then swelled and dissolved in the glycerol. The resultant solution was cooled to 50° to 70° C. and a concentrated aqueous solution of doxorubicin hydrochloride was added thereto. The whole was kneaded and mixed up. To this mixture was added a solution of sugar in the above-mentioned buffer, followed by agitation with an agitating/homogenizing mixer at 50° to 70° C. The osmotic pressure of the final aqueous medium was adjusted to render it substantially identical to the biological osmotic pressure.
1. Ultrasonic Method A:
The tip of a tip-type ultrasonicator was inserted into the container containing the crude liposomal dispersion and emulsification was carried out to give an aqueous liposomal dispersion with a liposome particle size of 50 nm or less.
2. Ultrasonic Method B:
The tip of a tip-type ultrasonicator was inserted into the container containing the crude liposomal dispersion and emulsification was carried out to give an aqueous liposomal dispersion with a liposome particle size of 50 to 200 nm.
3. Microfluidizer Method A:
The crude liposomal dispersion was treated in a microfluidizer for emulsification, to give an aqueous liposomal dispersion with a liposome particle size of 50 nm or less.
4. Microfluidizer Method B:
The crude liposomal dispersion was treated in a microfluidizer for emulsification, to give an aqueous liposomal dispersion with a liposome particle size of 50 to 200 nm.
5. Extrusion Method A:
The crude liposomal dispersion was subjected to high pressure filtration through a polycarbonate membrane filter with a pore size of 0.05 μm to give an aqueous liposomal dispersion with a liposome particle size of 50 nm or less.
6. Extrusion Method B:
The crude liposomal dispersion was subjected to high pressure filtration through a polycarbonate membrane filter with a pore size of 0.2 μm to give an aqueous liposomal dispersion with a particle size of 50 to 200 nm.
1. Particle Size and Number of Membranes:
For each aqueous dispersion of liposomes containing doxorubicin hydrochloride and for an aqueous liposomal dispersion reconstituted from each lyophilized liposomal preparation, liposome particle size determination was performed by the quasi-elastic light scattering method. That the liposomes obtained in each example has a plurality of membranes was confirmed by means of an electron microscope and on the basis of an estimated value derived from the encapsulation volume (L/M) determined with a water-soluble model drug and the particle size.
2. Encapsulation Efficiency of Drug:
For each aqueous dispersion of doxorubicin hydrochloride-containing liposomes and for an aqueous liposomal dispersion reconstituted from each lyophilized liposomal preparation, the encapsulation efficiency of doxorubicin hydrochloride in liposomes was determined by the ultracentrifugation method.
Table 3 shows the electrolyte concentration used in Examples 1 to 22. From the data in Tables 1, 2, 3, 4 and 5, it can be seen that when the electrolyte concentration is less than 40 mM, particularly less than 20 mM, the encapsulation efficiency is unexpectedly high.
3. Stability in Blood:
The aqueous liposomal dispersion (1.5 ml) reconstituted from doxorubicin hydrochloride-containing lyophilized liposomes was added to 5.8 ml of a rat serum and, after an hour of incubation at 37° C., the encapsulation efficiency of doxorubicin hydrochloride in liposomes was determined in the same manner as mentioned above.
As shown in Table 1, it was confirmed that, in the final liposomal products according to the invention, 90% or more (nearly to 100%) of doxorubicin hydrochloride can be encapsulated in liposomes and the final products are stable in the blood.
The liposomes of Example 3 were evaluated for antitumor activity. They were comparable to free doxorubicin hydrochloride in in vitro cell proliferation inhibiting effect (tumor cells: P388 mouse leukemia cells, QG56 human lung squamous cell carcinoma cells, HOC21 human ovarian cancer cells, and MKN-28 human stomach cancer cells) as well as in in vivo antitumor effect (MH-134 cancer-bearing mice).
The liposomes of Example 3 were subjected to safety testing in rats. Electrocardiography, clinical symptom observation, blood chemistry and other tests revealed that the liposomes were evidently lower in cardiotoxicity, alopecia incidence rate, diarrhea incidence rate, hemotoxicity and so on as compared with free doxorubicin hydrochloride.
As mentioned above, it has become evident that the doxorubicin hydrochloride-containing liposomal products, which is one embodiment of the present invention, can retain 90% or more of the doxorubicin hydrochloride added with good reproducibility, has very high stability in the blood and can reduce various toxicities intrinsic of doxorubicin hydrochloride.
The raw material used in Examples 1 to 22 is shown below:
DMPG: L-α-dimyristoylphosphatidyl-DL-glycerol (trade name: MGLS-4040, manufactured by Nippon Oil & Fats Co., Ltd.)
DPPG: L-α-dipalmitoylphosphatidyl-DL-glycerol (trade name: MGLS-6060, manufactured by Nippon Oil & Fats Co., Ltd.)
DSPG: L-α-distearoylphosphatidyl-DL-glycerol (trade name: MGLS-8080, manufactured by Nippon Oil & Fats Co., Ltd.)
Hydrogenated PG: Hydrogenated phosphatidylglycerol (manufactured by Asahi Chemical Industry Co., Ltd.) There is no particular trade name.
DMPG: L-α-dimyristoylphosphatidylglycerol (trade name: PhosphoLipid-DMPG, manufactured by Nippon Fine Chemical Co., Ltd.)
TABLE 1 - Encapsulation Efficiency ofParticle Active Ingre- Amounts of Membrane Components Size (nm) dient (%) Stabi- per 1.29 mM of Doxorubicin Hydro- Before After Before After lity chloride, mM (mole ratio to Aqueous Medium Preparation Lyoph- Lyoph- Lyoph- Lyoph- in active ingredient) Scale of Crude iliza- iliza- iliza- iliza- blood Example No. Charged Lipid Cholesterol Other Solutes pH (ml) Dispersion Sizing tion tion tion tion (%) Example 1 DMPG 11.4 (8.8) 14(10.9) eggPC 4 Sucrose- 4.0 10 Organic Extru- 81 103 100.0 99.9 89.1 (3.1) lactic solvent sion B acid method A Example 2 DMPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 2 Poly- Extru- 125 130 100.0 100.0 95.2 (1.6) lactic hydric sion B acid alcohol Example 3 DMPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 20 Organic Extru- 91 90 99.9 99.9 91.4 (1.6) lactic solvent sion B acid method A Example 4 DMPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 20 Organic Extru- 85 93 99.8 99.9 88.4 (1.6) lactic solvent sion B acid method B Example 5 DMPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 20 Organic Ultra- 156 178 99.7 100.0 86.5 (1.6) lactic solvent sonic B acid method A Example 6 DMPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 20 Organic Micro- 190 173 100.0 99.8 92.0 (1.6) lactic solvent fluid- acid method A izer B Example 7 DPPC 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 10 Organic Extru- 75 98 99.7 99.8 82.4 (1.6) lactic solvent sion B acid method A Example 8 DMPG 11.4 (8.8) 10(7.8) eggPC 2 Sucrose- 4.0 20 Organic Extru- 95 90 99.9 99.9 86.8 (1.6) lactic solvent sion B acid method A Example 9 DMPG 10 (7.8) 10(7.8) Sucrose- 4.0 10 Organic Extru- 120 111 100.0 99.7 82.2 lactic solvent sion B acid method A Example 10 DMPG 8 (6.2) 10(7.8) eggPC 2 Sucrose- 4.0 10 Organic Extru- 132 129 99.8 100.0 88.0 (1.6) lactic solvent sion B acid method A Example 11 DMPG 6 (4.7) 10(7.8) eggPC 4 Sucrose- 4.0 10 Organic Extru- 110 107 100.0 99.6 80.2 (3.1) lactic solvent sion B acid method A Example 12 DPPG 6 (4.7) 10(7.8) eggPC 4 Sucrose- 4.0 10 Organic Extru- 100 95 99.6 99.5 82.0 (3.1) lactic solvent sion B acid method A Example 13 DMPG 4 (3.1) 10(7.8) eggPC 6 Sucrose- 4.0 10 Organic Extru- 98 105 99.9 99.7 84.4 (4.7) lactic solvent sion B acid method A Example 14 DMPG 3 (2.3) 10(7.8) eggPC 7 Sucrose- 4.0 10 Organic Extru- 95 99 99.5 99.6 80.5 (5.4) lactic solvent sion B acid method A Example 15 DSPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 10 Organic Extru- 170 195 90.7 90.3 77.4 (1.6) lactic solvent sion B acid method A Example 16 Hydrogenated 12(9.3) eggPC 2 Sucrose- 4.0 20 Organic Extru- 167 200 91.0 90.4 75.3 PG 11.4 (8.8) (1.6) lactic solvent sion B acid method A Example 17 DMPG 11.4 (8.8) 8(6.2) eggPC 2 Sucrose- 4.0 20 Organic Extru- 99 103 99.7 99.8 70.7 (1.6) lactic solvent sion B acid method A Example 18 DSPG 5.2 (4.0) 7.7(6.0) DSPC 10% Aque- 7.4 20 Organic Ultra- 45 248 87.3 88.1 64.4 6.5 ous solu- solvent sonic A (5.0) tion of method A sucrose Example 19 DMPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 20 Organic Extru- 44 425 99.9 99.7 57.2 (1.6) lactic solvent sion A acid method A Example 20 DMPG 11.4 (8.8) 12(9.3) eggPC 2 Sucrose- 4.0 20 Organic Ultra- 49 223 -- 99.9 60.3 (1.6) lactic solvent sonic A acid method A Note 1: DMPG: sodium salt of Dimyristoylphosphatidylglycerol, DPPG: sodium salt of Dipalmitoylphosphatidylglycerol, DSPG: sodium salt of Distearoylphosphatidylglycerol, Hydrogenated PG: Hydrogenated phosphatidylglycerol, eggPC: sodium salt of Egg yolkderived phosphatidylcholine, DSPC: Distearoylphosphatidylcholine. Note 2: Sucroselactic acid: 9 mM lactate buffer supplemented with 9% sucrose.
TABLE 2__________________________________________________________________________ Encapsulation Efficiency of Particle Active Ingre- Size (nm) dient (%) Stabi-Amounts of Membrane Components, mM Bfore After Before After lity (mol ratio to active ingredient) Aqueous Medium Preparation Lyoph- Lyoph- Lyoph- Lyoph- inExam- Choles- Active Scale of Crude iliza- iliza- iliza- iliza- blood ple No. Charged Lipid terol Ingredient Solutes pH (ml) Dispersion Sizing tion tion tion tion (%)__________________________________________________________________________Exam- DMPG 52 (8.1) 48 (7.5) AMK 6.40 10% -- 150 Organic Extru- -- 146 -- 99.9 91.5 ple 21 sucrose solvent sion B method B Exam- DMPG 52 (15.2) 48 (14.0) SM 3.43 10% -- 150 Organic Extru- -- 131 -- 98.8 88.7 ple 22 sucrose solvent sion B method B__________________________________________________________________________ Note 3: AMK: Amikacin sulfate. SM: Streptomycin sulfate.
TABLE 3______________________________________Total Electrolyte Concentration in Examples 1 to 22. Concentration of Anionic Example No. Electrolytes Phospholipid______________________________________Example 1 16 mM DMPG Example 2 16 mM DMPG Example 3 16 mM DMPG Example 4 16 mM DMPG Example 5 16 mM DMPG Example 6 16 mM DMPG Example 7 16 mM DMPG Example 8 16 mM DMPG Example 9 15 mM DMPG Example 10 13 mM DMPG Example 11 11 mM DMPG Example 12 11 mM DMPG Example 13 9 mM DMPG Example 14 8 mM DMPG Example 15 16 mM DSPG Example 16 16 mM H-PG Example 17 16 mM DMPG Example 18 10 mM DSPG Example 19 15 mM DMPG Example 20 16 mM DMPG Example 21 0 mM DMPG Example 22 0 mM DMPG______________________________________
TABLE 4______________________________________Effect of Concentration of Electrolytes on Encapsulation Efficiency of Doxorubicin [ADM] into Liposomes Cpncentration Molar ratio Encapsulation of electrolytes (DMPG/ADM2) Appearance3 efficiency (%)______________________________________15 mM 8.7 good 99.6 42 mM 8.7 good 97.6 69 mM 8.7 good 95.5 96 mM 8.7 good 94.4 123 mM 8.7 good 92.7 150 mM 8.7 good 90.4 177 mM 8.7 good 86.2 204 mM 8.7 good 84.5 231 mM 8.7 good 82.8 258 mM 8.7 good 81.3 285 mM 8.7 good 80.5______________________________________ 1 Dimyristoylphosphatidylglycerol [DMPG]/Egg yolk phosphatidylcholin [Egg/PC]/Cholesterol [Chol] = 15 mM/2.7 mM/16 mM. 2 Concentration of ADM = 1.0 mg/ml (1.72 mM). 3 Particle size was not determined.
TABLE 5______________________________________Effect of Concentration of Electrolytes on Encapsulation Efficiency of Doxorubicin [ADM] into Liposomes1 II Concentration Molar ratio Encapsulation of electrolytes (DMPG/ADM2) Appearance3 efficiency (%)______________________________________26 mM 15.1 good 98.7 41 mM 15.1 good 97.9 56 mM 15.1 good 97.2 71 mM 15.1 good 96.3 86 mM 15.1 good 96.1 116 mM 15.1 good 96.0 146 mM 15.1 good 95.4 176 mM 15.1 good 94.5 221 mM 15.1 good 94.0 266 mM 15.1 good 93.4 296 mM 15.1 good 92.5 326 mM 15.1 good 91.9______________________________________ 1 Dimyristoylphosphatidylglycerol [DMPG]/Cholesterol [Chol] = 26 mM/24 mM. 2 Concentration of ADM = 1.0 mg/ml (1.72 mM). 3 Particle size was not determined.
Also, Table 2 shows the results of the case of other drugs than doxorubicin hydrochloride, that is, amikacin sulfate and streptomycin sulfate. Similar to doxorubicin hydrochloride, these drugs which have cation moieties can be encapsulated with a very high encapsulation efficiency in the liposomal products according to the invention. In addition, these liposomal products are very highly stable in the blood.
While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4310506 *||Feb 20, 1980||Jan 12, 1982||California Institute Of Technology||Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species|
|US4756910 *||Nov 25, 1986||Jul 12, 1988||Kabushiki Kaisha Vitamin Kenkyusyo||Adriamycin-entrapping liposome preparation|
|US4769250 *||Oct 26, 1987||Sep 6, 1988||Vestar, Inc.||Antracycline antineoplastic agents encapsulated in phospholipid vesicle particles and methods for using same for tumor therapy|
|US4818537 *||Oct 21, 1986||Apr 4, 1989||Liposome Technology, Inc.||Liposome composition for treating dry eye|
|US4830858 *||Feb 11, 1985||May 16, 1989||E. R. Squibb & Sons, Inc.||Spray-drying method for preparing liposomes and products produced thereby|
|US4873088 *||Jul 13, 1987||Oct 10, 1989||Liposome Technology, Inc.||Liposome drug delivery method and composition|
|US4906477 *||Feb 8, 1988||Mar 6, 1990||Kabushiki Kaisha Vitamin Kenkyusyo||Antineoplastic agent-entrapping liposomes|
|US4927571 *||May 18, 1987||May 22, 1990||Liposome Technology, Inc.||Preparation of injectable doxorubicin/liposome suspension|
|EP0219922A2 *||Mar 4, 1986||Apr 29, 1987||Vestar, Inc.||Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles|
|EP0274174A1 *||Jan 9, 1987||Jul 13, 1988||Yissum Research Development Company Of The Hebrew University Of Jerusalem||Liposome/anthraquinone drug composition and method|
|WO1982003769A1 *||Apr 14, 1982||Nov 11, 1982||Georgetown Univ||Anthracycline glycoside compositions,their use and preparation|
|WO1988004573A1 *||Jan 13, 1987||Jun 30, 1988||The Liposome Company, Inc.||Liposome preparation and antibiotic|
|1||*||Grant & Hackh s Chemical dictionary. 1987. p. 205.|
|2||Grant & Hackh's Chemical dictionary. 1987. p. 205.|
|3||P. Buri et al. "Formes Pharmaceutiques Nouvelles", 1985, Technique et Documentation (Lavoisier), Paris FR, pp. 470 and 484.|
|4||*||P. Buri et al. Formes Pharmaceutiques Nouvelles , 1985, Technique et Documentation (Lavoisier), Paris FR, pp. 470 and 484.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7125568||Apr 29, 2002||Oct 24, 2006||Sung Michael T||Lipophilic drug compositions|
|US7390506||Mar 3, 2006||Jun 24, 2008||Sung Michael T||Lipophilic drug compositions|
|US7964580||Mar 21, 2008||Jun 21, 2011||Pharmasset, Inc.||Nucleoside phosphoramidate prodrugs|
|US8173621||Jun 5, 2009||May 8, 2012||Gilead Pharmasset Llc||Nucleoside cyclicphosphates|
|US8551973||Dec 23, 2009||Oct 8, 2013||Gilead Pharmasset Llc||Nucleoside analogs|
|US8563530||Mar 31, 2011||Oct 22, 2013||Gilead Pharmassel LLC||Purine nucleoside phosphoramidate|
|US8580765||Sep 11, 2012||Nov 12, 2013||Gilead Pharmasset Llc||Nucleoside phosphoramidate prodrugs|
|US8618076||Mar 31, 2011||Dec 31, 2013||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US8629263||Jan 25, 2013||Jan 14, 2014||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US8633309||Jan 10, 2013||Jan 21, 2014||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US8642756||May 20, 2010||Feb 4, 2014||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US8716262||Dec 23, 2009||May 6, 2014||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US8716263||Dec 23, 2009||May 6, 2014||Gilead Pharmasset Llc||Synthesis of purine nucleosides|
|US8735372||Oct 18, 2013||May 27, 2014||Gilead Pharmasset Llc||Nucleoside phosphoramidate prodrugs|
|US8735569||Jul 8, 2013||May 27, 2014||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US8759510||Apr 5, 2012||Jun 24, 2014||Gilead Pharmasset Llc||Nucleoside cyclicphosphates|
|US8841275||Nov 30, 2011||Sep 23, 2014||Gilead Pharmasset Llc||2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections|
|US8859756||Mar 31, 2011||Oct 14, 2014||Gilead Pharmasset Llc||Stereoselective synthesis of phosphorus containing actives|
|US8889159||Nov 27, 2012||Nov 18, 2014||Gilead Pharmasset Llc||Compositions and methods for treating hepatitis C virus|
|US8906880||Apr 17, 2014||Dec 9, 2014||Gilead Pharmasset Llc||Nucleoside phosphoramidate prodrugs|
|US8957045||Feb 25, 2013||Feb 17, 2015||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US8957046||Apr 16, 2014||Feb 17, 2015||Gilead Pharmasset Llc||Nucleoside phosphoramidate prodrugs|
|US9005655 *||Jul 17, 2008||Apr 14, 2015||Bharat Serums & Vaccines Ltd.||Non-pegylated long-circulating liposomes|
|US9045520||Jun 7, 2012||Jun 2, 2015||Gilead Pharmasset Llc||Synthesis of purine nucleosides|
|US9085573||Aug 29, 2013||Jul 21, 2015||Gilead Pharmasset Llc||Nucleoside phosphoramidate prodrugs|
|US9206217||Jan 2, 2013||Dec 8, 2015||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US9284342||Jun 24, 2013||Mar 15, 2016||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US9394331||Jul 15, 2014||Jul 19, 2016||Gilead Pharmasset Llc||2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections|
|US9549941||Nov 11, 2014||Jan 24, 2017||Gilead Pharmasset Llc||Compositions and methods for treating hepatitis C virus|
|US9585906||Mar 12, 2015||Mar 7, 2017||Gilead Pharmasset Llc||Nucleoside phosphoramidate prodrugs|
|US9637512||Jan 10, 2014||May 2, 2017||Gilead Pharmasset Llc||Nucleoside phosphoramidates|
|US20030108596 *||Apr 29, 2002||Jun 12, 2003||Sung Michael T.||Lipophilic drug compositions|
|US20040057988 *||Nov 9, 2001||Mar 25, 2004||Eishun Tsuchida||Method for preparing microsome dispersion|
|US20050260256 *||Sep 27, 2002||Nov 24, 2005||Hill Knut R||Methods and apparatus for extrusion of vesicles at high pressure|
|US20060037942 *||Jun 30, 2005||Feb 23, 2006||Seong-Kyu Yun||Slurry, chemical mechanical polishing method using the slurry, and method of forming a surface of a capacitor using the slurry|
|US20070122469 *||Jan 29, 2007||May 31, 2007||Eishun Tsuchida||Method for producing a vesicle dispersion|
|US20080279927 *||Jul 17, 2008||Nov 13, 2008||Bharat Serums & Vaccines Ltd||Non-Pegylated Long-Circulating Liposomes|
|US20090017108 *||Jul 11, 2008||Jan 15, 2009||Alexander Yuzhakov||Liposome compositions for treatment of hepatitis C|
|US20090053302 *||Mar 5, 2007||Feb 26, 2009||Parthenios Boulikas||Cancer treatments|
|US20100016251 *||Mar 21, 2008||Jan 21, 2010||Pharmasset, Inc.||Nucleoside phosphoramidate prodrugs|
|US20100298257 *||May 20, 2010||Nov 25, 2010||Pharmasset, Inc.||Nucleoside phosphoramidates|
|US20130266700 *||Jun 14, 2011||Oct 10, 2013||Abbott Laboratories||Ultrasonically-assisted extrusion methods for manufacturing powdered nutritional products|
|CN103630508A *||Nov 19, 2013||Mar 12, 2014||常州金远药业制造有限公司||Method for measuring encapsulation efficiency of doxorubicin hydrochloride liposomal|
|EP2609923A2||Mar 31, 2011||Jul 3, 2013||Gilead Pharmasset LLC||Nucleoside Phosphoramidates|
|EP2610264A2||May 20, 2010||Jul 3, 2013||Gilead Pharmasset LLC||N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production|
|EP2671888A1||Dec 23, 2009||Dec 11, 2013||Gilead Pharmasset LLC||3',5'-cyclic nucleoside phosphate analogues|
|EP2752422A1||Mar 31, 2011||Jul 9, 2014||Gilead Pharmasset LLC||Stereoselective synthesis of phosphorus containing actives|
|EP2910562A1||May 20, 2010||Aug 26, 2015||Gilead Pharmasset LLC||N-[(2'r)-2'-deoxy-2 '-fluoro-2'-methyl-p-phenyl-5 '-uridylyl]-l-alanine 1-methylethyl ester in crystalline form|
|EP2913337A1||May 20, 2010||Sep 2, 2015||Gilead Pharmasset LLC||N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production|
|EP3042910A2||Nov 30, 2011||Jul 13, 2016||Gilead Pharmasset LLC||2'-spiro-nucleosides for use in the therapy of hepatitis c|
|WO2007099377A2 *||Mar 5, 2007||Sep 7, 2007||Parthenios Boulikas||Cancer treatments|
|WO2007099377A3 *||Mar 5, 2007||Apr 17, 2008||Parthenios Boulikas||Cancer treatments|
|WO2008121634A2||Mar 26, 2008||Oct 9, 2008||Pharmasset, Inc.||Nucleoside phosphoramidate prodrugs|
|WO2010075517A2||Dec 23, 2009||Jul 1, 2010||Pharmasset, Inc.||Nucleoside analogs|
|WO2010075549A2||Dec 23, 2009||Jul 1, 2010||Pharmasset, Inc.||Nucleoside phosphoramidates|
|WO2010075554A1||Dec 23, 2009||Jul 1, 2010||Pharmasset, Inc.||Synthesis of purine nucleosides|
|WO2010135569A1||May 20, 2010||Nov 25, 2010||Pharmasset, Inc.||N- [ (2 ' r) -2 ' -deoxy-2 ' -fluoro-2 ' -methyl-p-phenyl-5 ' -uridylyl] -l-alanine 1-methylethyl ester and process for its production|
|WO2011123645A2||Mar 31, 2011||Oct 6, 2011||Pharmasset, Inc.||Nucleoside phosphoramidates|
|WO2011123668A2||Mar 31, 2011||Oct 6, 2011||Pharmasset, Inc.||Stereoselective synthesis of phosphorus containing actives|
|WO2011123672A1||Mar 31, 2011||Oct 6, 2011||Pharmasset, Inc.||Purine nucleoside phosphoramidate|
|WO2012075140A1||Nov 30, 2011||Jun 7, 2012||Pharmasset, Inc.||Compounds|
|U.S. Classification||424/450, 264/41, 264/43|
|Oct 15, 2003||FPAY||Fee payment|
Year of fee payment: 4
|Oct 12, 2007||FPAY||Fee payment|
Year of fee payment: 8
|Dec 19, 2011||REMI||Maintenance fee reminder mailed|
|May 9, 2012||LAPS||Lapse for failure to pay maintenance fees|
|Jun 26, 2012||FP||Expired due to failure to pay maintenance fee|
Effective date: 20120509